Predicting Circulating CA125 Levels among Healthy Premenopausal Women

Sasamoto, Naoko; Babić, Ana; Rosner, Bernard; Fortner, Renée T.; Vitonis, Allison F.; Yamamoto, Hidemi S.; Fichorova, Raina N.; Tjønneland, Anne; Hansen, Louise; Overvad, Kim; Kvaskoff, Marina; Fournier, Agnès; Mancini, Francesca Romana; Boeing, Heiner; Trichopoulou, Antonia; Peppa, Eleni; Karakatsani, Anna; Palli, Domenico; Pala, Valeria; Mattiello, Amalia; Tumino, Rosario; Grasso, Chiara; Onland‐Moret, N. Charlotte; Weiderpass, Elisabete; Quiŕos, J. Ramón; Luján-Barroso, Leila; Rodríguez‐Barranco, Miguel; Colorado‐Yohar, Sandra; Barricarte, Aurelio; Dorronsoro, Miren; Idahl, Annika; Lundin, Eva; Sartor, Hanna; Khaw, Kay-Tee; Key, Timothy J.; Muller, David C.; Riboli, Elio; Gunter, Marc J.; Dossus, Laure; Kaaks, Rudolf; Cramer, Daniel W.; Tworoger, Shelley S.; Terry, Kathryn L.

doi:10.1158/1055-9965.epi-18-1120

Cited by 11 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In premenopausal women, this study demonstrated that 5–10 years’ duration of OCP use, compared to duration < 2 years, was less likely to be associated with CA125 level ≥ 35 U/ml. Sasamoto et al had shown that longer duration of OCP use (> 4 years), compared to duration < 2 years, was associated with lower CA125 level in premenopausal women without OC [ 19 ]. This finding correlates with the duration-dependent protective association between longer OCP use and risk reduction of OC by suppressing ovulation [ 28 – 30 ].…”

Section: Discussionmentioning

confidence: 99%

Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study

Zhang

Cao

2022

BMC Cancer

View full text Add to dashboard Cite

Background Cancer antigen 125 (CA125) is clinically used to monitor response to therapy in ovarian cancer and has been proposed for use in detecting ovarian cancer. This population-based study examines how demographic characteristics, gynecologic/reproductive history, chronic non-malignant medical conditions, history of non-ovarian cancer, lifestyle practices, and biomarkers of inflammation correlate with serum CA125 in both premenopausal and postmenopausal women without ovarian cancer across the United States. Methods Participants were identified from the National Health and Nutrition Examination Survey 2001–2002. Linear and logistic regression models were applied. Results Higher CA125 levels were found to correlate with younger age, Non-Hispanic White race/ethnicity, and lower body mass index. In premenopausal women (N = 1157), current smoking was associated with lower CA125 (− 24.95%, p = 0.008), and history of non-ovarian cancer was associated with higher CA125 (40.64%, p = 0.045) by multivariable linear regression; both current smoking (odds ratio (OR) = 0.42, p = 0.043) and oral contraceptive pill (OCP) use of 5–10 years (OR = 0.31, p = 0.032) were less likely to be associated with having CA125 level ≥ 35 U/ml by multivariable logistic regression. In postmenopausal women (N = 1116), coronary artery disease (CAD) history was associated with higher CA125 (28.27%, p = 0.047) by multivariable linear regression; history of CAD (OR = 5.00, p = 0.011), history of breastfeeding (OR = 2.46, p = 0.026), and increased CRP level (OR = 1.41, p = 0.042) were more likely to be associated with having CA125 level ≥ 35 U/ml by multivariable logistic regression. Conclusions Results suggest CA125 is lower in premenopausal women who are current smokers and OCP users of moderately longer duration but higher in those with non-ovarian cancer. CA125 is higher in those postmenopausal women with CAD, history of breastfeeding and elevated CRP level. These associations can inform clinical interpretation of individual patients’ CA125 levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study

Zhang

Cao

2022

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first study that reported demographic characteristics in relation to CA125 values in healthy adolescents and young women. CA125 is known to be influenced by personal characteristics in healthy individuals [ 12 , 35 – 38 ], and only two studies have examined correlates of CA125 in premenopausal women, with the youngest age category being women age <30 years [ 12 , 35 ]. Consistent with prior studies, we observed that current smoking and hormone use at blood draw was associated with lower CA125, and blood draw at follicular phase was associated with higher CA125 in controls.…”

Section: Discussionmentioning

confidence: 99%

“…Cancer Antigen125 (CA125) is a high molecular-weight glycoprotein normally expressed on tissues derived from the coelomic and mullerian epithelia including the uterus endometrium [8]. CA125 has been reported to be elevated in endometriosis patients and is the most commonly described, extensively studied endometriosis biomarker to date [6,[9][10][11][12][13]. A recent report suggested that CA125 may be predictive of endometriosis in symptomatic women with gynecological pain and/or subfertility [10].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of CA125 in relation to pain symptoms among adolescents and young adult women with and without surgically-confirmed endometriosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Endometriosis is a painful gynecologic disease affecting one in ten reproductive aged women worldwide. Few studies have correlated this symptomatology with biomarker levels among women with and without endometriosis, and no studies correlating pain with biomarker levels have been performed in young patient populations. The purpose of this study was to examine whether CA125 correlates with different types and severity of pain among adolescents and young women with and without endometriosis and assess its performance as an endometriosis biomarker among those presenting with dysmenorrhea in this young population. Reproductive-aged women with laparoscopically-confirmed endometriosis (n = 282) and controls (n = 293) who participated in The Women's Health Study: From Adolescence to Adulthood (A2A), a cohort of adolescents and young women enrolled from 2012-2018, were included in this cross-sectional analysis. Plasma CA125 values were measured using WERF EPHect compliant blood samples collected at enrollment. Average CA125 were calculated by self-reported pain type (i.e. dysmenorrhea, non-cyclic/general pelvic pain, dyspareunia), severity, and frequency in endometriosis cases and controls. Median age at blood draw was 24 years in controls and 17 years in cases, with 68% and 89% non-Hispanic white, respectively. Most endometriosis cases (95%) were rASRM stage I/II. Average CA125 values were 12.5 U/mL in controls and 12.1 U/mL in cases adjusted for age. CA125 did not differ by pain type, its severity, or frequency in endometriosis cases or controls. Among participants who reported dysmenorrhea, CA125 did not discriminate endometriosis cases from controls using cutoff of 35 U/mL (AUC = 0.51, 95%CI = 0.50-0.53). Among adolescents and young adult women, CA125 did not correlate with pain type. CA125

show abstract

“…CA125 levels were extracted from clinical records. Before FUAS, serum samples for CA125 test were routinely collected, transported to the laboratory at room temperature, and measured by two‐step immunoassay for quantitative determination with flexible assay protocols within 1 day before FUAS 15 . Thereafter, CA125 was assayed in a central laboratory and the laboratory personnel were blinded to the clinical data 16 …”

Section: Methodsmentioning

confidence: 99%

Serum CA125 as a biomarker for dysmenorrhea in adenomyosis

Tang

Wen

Xiang

et al. 2023

Intl J Gynecology & Obste

View full text Add to dashboard Cite

ObjectiveTo explore the association between CA125 and dysmenorrhea in adenomyosis, and the factors affecting CA125 in adenomyosis.MethodsPatients were grouped a the presence of dysmenorrhea. The receiver operating characteristic (ROC) curve was applied to assess the utility of CA125 for dysmenorrhea. Binary logistic regression was employed to identify the factors associating dysmenorrhea and CA125 level.ResultsPatients in the dysmenorrhea group had higher CA125 levels than those in the non‐dysmenorrhea group. For those with dysmenorrhea, CA125 levels of diffuse subtype group were higher than those of the focal subtype group. The CA125 level of 35 U/mL was validated as the optimal cut‐point for dysmenorrhea in ROC curves. Compared with patients whose CA125 was 35 U/mL or less, those with CA125 levels greater than 35 U/mL were more likely to have dysmenorrhea. Thereafter, the multiple regression analysis showed that adenomyotic lesion volume was positively correlated with CA125 level in the total cohort and subtype groups, while age was negatively correlated with CA125 level in the total cohort and diffuse subtype.ConclusionsThe pathogenesis of adenomyosis is not clear. CA125 was associated with dysmenorrhea in adenomyosis, and, furthermore, CA125 level is positively correlated with the severity of the disease.

show abstract

Predicting Circulating CA125 Levels among Healthy Premenopausal Women

Cited by 11 publications

References 30 publications

Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study

Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study

Evaluation of CA125 in relation to pain symptoms among adolescents and young adult women with and without surgically-confirmed endometriosis

Serum CA125 as a biomarker for dysmenorrhea in adenomyosis

Contact Info

Product

Resources

About